These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 10617295)

  • 21. Assessment methods of inhaled aerosols: technical aspects and applications.
    Jaafar-Maalej C; Andrieu V; Elaissari A; Fessi H
    Expert Opin Drug Deliv; 2009 Sep; 6(9):941-59. PubMed ID: 19637979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug delivery systems for cyclosporine: achievements and complications.
    Klyashchitsky BA; Owen AJ
    J Drug Target; 1998; 5(6):443-58. PubMed ID: 9783676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery.
    Shoyele SA; Slowey A
    Int J Pharm; 2006 May; 314(1):1-8. PubMed ID: 16563674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pulmonary vaccine delivery.
    Lu D; Hickey AJ
    Expert Rev Vaccines; 2007 Apr; 6(2):213-26. PubMed ID: 17408371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liposomal formulations for inhalation.
    Cipolla D; Gonda I; Chan HK
    Ther Deliv; 2013 Aug; 4(8):1047-72. PubMed ID: 23919478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro evaluation of the effect of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin A.
    Matilainen L; Järvinen K; Toropainen T; Näsi E; Auriola S; Järvinen T; Jarho P
    Int J Pharm; 2006 Aug; 318(1-2):41-8. PubMed ID: 16624508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aerosol delivery devices and obstructive airway disease.
    O'Riordan TG
    Expert Rev Med Devices; 2005 Mar; 2(2):197-203. PubMed ID: 16293056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanoparticle formulations in pulmonary drug delivery.
    Bailey MM; Berkland CJ
    Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic treatment by inhalation of macromolecules--principles, problems, and examples.
    Siekmeier R; Scheuch G
    J Physiol Pharmacol; 2008 Dec; 59 Suppl 6():53-79. PubMed ID: 19218633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation.
    Behr J; Zimmermann G; Baumgartner R; Leuchte H; Neurohr C; Brand P; Herpich C; Sommerer K; Seitz J; Menges G; Tillmanns S; Keller M;
    J Aerosol Med Pulm Drug Deliv; 2009 Jun; 22(2):121-30. PubMed ID: 19422312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Aerosol generation and delivery systems for pulmonary drug administration: theory and practice].
    Newhouse MT
    Z Gesamte Inn Med; 1993 Aug; 48(8):363-8. PubMed ID: 8379217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel.
    Hureaux J; Lagarce F; Gagnadoux F; Vecellio L; Clavreul A; Roger E; Kempf M; Racineux JL; Diot P; Benoit JP; Urban T
    Eur J Pharm Biopharm; 2009 Oct; 73(2):239-46. PubMed ID: 19560538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamics of aerosol size during inhalation: hygroscopic growth of commercial nebulizer formulations.
    Haddrell AE; Davies JF; Miles RE; Reid JP; Dailey LA; Murnane D
    Int J Pharm; 2014 Mar; 463(1):50-61. PubMed ID: 24406674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of realistic airflow rate on aerosol generation by nebulizers.
    Vecellio L; Kippax P; Rouquette S; Diot P
    Int J Pharm; 2009 Apr; 371(1-2):99-105. PubMed ID: 19150494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical perspectives on pulmonary systemic and macromolecular delivery.
    Scheuch G; Kohlhaeufl MJ; Brand P; Siekmeier R
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):996-1008. PubMed ID: 16996638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aerosol delivery devices in the treatment of asthma.
    Hess DR
    Respir Care; 2008 Jun; 53(6):699-723; discussion 723-5. PubMed ID: 18501026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization and in vitro evaluation of the formoterol/cyclodextrin complex for pulmonary administration by nebulization.
    Thi TH; Azaroual N; Flament MP
    Eur J Pharm Biopharm; 2009 May; 72(1):214-8. PubMed ID: 19010412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can in vitro particle size measurements be used to predict pulmonary deposition of aerosol from inhalers?
    Thiel CG
    J Aerosol Med; 1998; 11 Suppl 1():S43-52. PubMed ID: 10180732
    [No Abstract]   [Full Text] [Related]  

  • 39. Aerosol delivery through an artificial airway.
    MacIntyre NR
    Respir Care; 2002 Nov; 47(11):1279-88; discussion 1285-9. PubMed ID: 12425743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dry powder inhalers for pulmonary drug delivery.
    Frijlink HW; De Boer AH
    Expert Opin Drug Deliv; 2004 Nov; 1(1):67-86. PubMed ID: 16296721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.